Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharm Res. 2011 Apr;28(4):920-33. doi: 10.1007/s11095-010-0297-1. Epub 2010 Oct 23.

Strategies for the assessment of protein aggregates in pharmaceutical biotech product development.

Author information

1
Biological and Sterile Product Development, MSD, Oss, The Netherlands.

Abstract

Within the European Immunogenicity Platform (EIP) ( http://www.e-i-p.eu ), the Protein Characterization Subcommittee (EIP-PCS) has been established to discuss and exchange experience of protein characterization in relation to unwanted immunogenicity. In this commentary, we, as representatives of EIP-PCS, review the current state of methods for analysis of protein aggregates. Moreover, we elaborate on why these methods should be used during product development and make recommendations to the biotech community with regard to strategies for their application during the development of protein therapeutics.

PMID:
20972611
PMCID:
PMC3063870
DOI:
10.1007/s11095-010-0297-1
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Support Center